Leaflet LAMIVUDINA MYLAN 150mg film-coated tablets
Indicated for: HIV-1 infection; chronic hepatitis B
Route of administration: oral
Substance: lamivudine (nucleoside/nucleotide reverse transcriptase inhibitor)
ATC: J05AF05 (Antiinfectives for systemic use | Direct acting antivirals | Nucleoside and nucleotide reverse transcriptase inhibitors)
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Lamivudine is an antiviral drug used to treat human immunodeficiency virus (HIV) infection and chronic hepatitis B. It belongs to the class of nucleoside reverse transcriptase inhibitors (NRTIs) and works by blocking viral replication, preventing the virus from multiplying in the body.
It is used in combination therapy for HIV, helping to suppress viral load and maintain immune system function. In chronic hepatitis B, lamivudine can reduce liver inflammation and slow disease progression, although prolonged use may lead to viral resistance.
It is administered orally, once daily, and is well tolerated by most patients. Compared to other antivirals, it has a favorable safety profile, making it suitable for long-term use.
Side effects may include nausea, headache, fatigue, diarrhea, and, in rare cases, liver impairment or lactic acidosis. Regular monitoring is recommended to prevent the development of drug resistance.
General data about LAMIVUDINA MYLAN 150mg
- Substance: lamivudine
- Date of latest medicines list: 01-06-2022
- Product code: W68801001
- Concentration: 150mg
- Pharmaceutical form: film-coated tablets
- Quantity: 30
- Product type: Generic medicine
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for lamivudine
Concentrations available for lamivudine
- 100mg
- 10mg/ml
- 150mg
- 300mg
- 5mg/ml